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Abstract
BACKGROUND 
Vedolizumab (VDZ), a humanised monoclonal antibody that selectively inhibits 
alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative 
colitis (UC) patients.
AIM 
To assess the efficacy and safety of VDZ in the real-world management of UC in a 
large multicenter cohort involving two countries and to identify predictors of 
achieving remission.
METHODS 
A retrospective review of Australian and Oxford, United Kingdom data for UC 
patients. Clinical response at 3 mo, endoscopic remission at 6 mo and clinical 
remission at 3, 6 and 12 mo were assessed. Cox regression models and Kaplan 
Meier curves were performed to assess the time to remission, time to failure and 
the covariates influencing them. Safety outcomes were recorded.
RESULTS 
Three hundred and three UC patients from 14 centres in Australia and United 
Kingdom, [60% n = 182, anti-TNF naïve] were included. The clinical response was 
79% at 3 mo with more Australian patients achieving clinical response compared 
to Oxford (83% vs 70% P = 0.01). Clinical remission for all patients was 56%, 62% 
and 60% at 3, 6 and 12 mo respectively. Anti-TNF naive patients were more likely 
to achieve remission than exposed patients at all the time points (3 mo 66% vs 40% 
P < 0.001, 6 mo 73% vs 46% P < 0.001, 12 mo 66% vs 51% P = 0.03). More 
Australian patients achieved endoscopic remission at 6 mo compared to Oxford 
(69% vs 43% P = 0.01). On multi-variate analysis, anti-TNF naïve patients were 1.8 
(95%CI: 1.3-2.3) times more likely to achieve remission than anti-TNF exposed (P 
< 0.001). 32 patients (11%) had colectomy by 12 mo.
CONCLUSION 
VDZ was safe and effective with 60% of UC patients achieving clinical remission 
at 12 mo and prior anti-TNF exposure influenced this outcome.
Key words: Vedolizumab; Ulcerative colitis; Outcomes
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Core tip: Vedolizumab (VDZ) is a gut selective anti-integrin used for treatment of 
Ulcerative colitis (UC). Evidence is needed to support its use in real life setting involving 
multiple centers and two countries to reduce physician, site and country biases. This is a 
retrospective review of prospectively collected database involving 303 UC patients from 
Australia and Oxford, United Kingdom treated with VDZ. Clinical response was observed 
in 79% of patients at 3 mo and clinical remission in 56%, 62% and 60% at 3 mo, 6 mo and 
12 mo respectively. Anti-tumor necrosis factor (anti-TNF) naïve patients were 1.8 times 
more likely to achieve remission than anti-TNF exposed and 11% of patients required 
colectomy by 12 mo. We concluded that VDZ is a safe and effective biologic medication 
used for treatment of UC.
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INTRODUCTION
The aim of treatment in ulcerative colitis (UC) is to achieve sustained clinical, mucosal 
and histological healing[1,2]. The choice of treatment depends on several factors 
including induction, or maintenance, of disease remission, severity of disease, extent 
and location of bowel involvement, disease phenotype and individual characteristics 
of the drug and patient. The use of conventional medications may be limited either by 
a lack of efficacy (5-aminosalicylates) or side effects [steroids/azathioprine (AZA)/6 
mercaptopurine (6MP)/methotrexate (MTX)][3]. Its’ use, however, is not without 
potential side effects including, development of opportunistic infections, reactivation 
of tuberculosis and an increased risk of melanoma[4].
Vedolizumab (VDZ), a humanised monoclonal antibody, selectively inhibits the 
migration of alpha4-beta7 inflammatory cells to the gastrointestinal tract, making it a 
biological agent without systemic immunosuppression and thus potentially reducing 
side-effects. In GEMINI 1, the randomised, double-blind placebo-controlled trial of 
VDZ in UC, the response rate for induction at week six was 47.1% with a response rate 
of 41.8% at week fifty two after eight-weekly VDZ treatments[5]. Patients enrolled in 
clinical trials, however, do not entirely represent the patients seen in routine clinical 
practice as demonstrated by a retrospective study where only 31% of 206 patients with 
moderate-to-severe inflammatory bowel disease (IBD) were eligible to participate in 
such a clinical trial[6].
Our aim was to assess the response and remission rates to VDZ in the real world, 
the time taken to achieve this, mucosal healing rates, adverse/serious events, the rates 
of colectomy and the predictors influencing remission in the first 12 mo of VDZ 
therapy through a multicenter consortium in a real-world setting.
MATERIALS AND METHODS
Study design
This was a multicenter retrospective review of prospectively collected data involving 
14 IBD centers in Australia New Zealand inflammatory bowel disease consortium and 
data was also collected at a major IBD center in United Kingdom, thus reducing 
physician, site and country bias. All the centers involved in the study had a dedicated 
IBD team. In Australia, patients with UC refractory to conventional treatment, which 
was defined as failure of three, or more, mo of a 5-aminosalycylate and failure of three 
or more mo of an immunomodulator (AZA, 6MP or MTX) and 6 wk weaning dose of 
prednisolone that commenced at 40mg per day or more, were able to access VDZ from 
2015 through the government funded pharmaceutical benefit scheme (PBS). In the 
United Kingdom, VDZ was given to patients at the physicians’ discretion if the 
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conventional treatment and/or anti-tumor necrosis factor (anti-TNF) medications had 
failed to control the disease.
Consecutive patients with UC diagnosed as per the standard criteria[7] who received 
at least induction VDZ therapy were considered for the study. All patients who 
finished VDZ induction therapy were included in the study for analysis. VDZ was 
given as standard intravenous (IV) induction dosing of 300mg at 0, 2 and 6 wk 
followed by maintenance therapy of 8 weekly IV infusions. Patients continued to take, 
or wean off, steroids, 5-aminosalicylates (oral and rectal therapy) as deemed 
appropriate by the treating physician. Patients taking immunosuppressant 
medications, including AZA, 6MP, MTX orally, or rectal tacrolimus, continued on 
these medications under the treating physicians’ preference as guided by the disease 
control. There were no mandated changes to a patient’s regular IBD medications. The 
use of steroids and/or immunomodulators and their time of cessation was recorded 
for analysis.
A retrospective review of the IBD databases that contained prospectively-entered 
data included baseline patient demographics and disease characteristics classified by 
the Montreal classification[8], concomitant use of steroids and immunomodulator 
medications, prior exposure to anti-TNF medications, adverse events and colectomy 
rates.
Assessments tools and criteria
The Montreal classification was used to classify UC[8]. The Partial Mayo clinical score 
was used to assess disease control and is composed of 3 items, which includes stool 
frequency, rectal bleeding and the physician global assessment which were each 
scored individually from 0 to 3 at baseline, 3, 6 and 12 mo. The higher the score, more 
severe the disease and maximum score was 9. The Mayo endoscopic score (MES) is 
classified into four levels of severity from 0-4 based on mucosal friability, vascular 
pattern, friability and erosions. Mayo 0-1 was inactive disease while Mayo 2 and Mayo 
3 were mild-moderate and moderate-severe disease respectively. Ulcerative colitis 
endoscopic index of severity (UCEIS) is composed of 3 items, which includes vascular 
pattern, bleeding and erosions/ulcers with score ranging from 0-2 for vascular pattern 
and scores 0-3 for bleeding and erosions/ulcers with higher scores indicating severe 
disease and the maximum score was 9. The response and remission to VDZ was 
assessed clinically using partial Mayo clinical score in both Australia and the United 
Kingdom sites. MES was used for assessing endoscopic appearance in Australia, and 
the UCEIS was used in the United Kingdom.
Evaluation of clinical efficiency at 3, 6 and 12 mo
Induction: Clinical efficiency of VDZ induction therapy was assessed as either clinical 
response or clinical remission at 3 mo. A response to VDZ was defined as a decrease in 
the Partial Mayo score of ≥ 3 from baseline, while clinical remission was defined as 
Partial Mayo score of < 2.
Maintenance
Clinical efficacy of VDZ was also assessed at 6 mo and 12 mo of VDZ therapy. The 
Partial Mayo score again was used to assess clinical response and clinical remission. 
Data was collected if VDZ was ceased due to side-effects, or loss of response (LOR) 
that resulted in a switch of the therapy away from VDZ, or surgery if it was required.
Endoscopic assessment of disease control was undertaken after approximately 6 mo 
of VDZ. An MES of 0 or 1 was defined as an endoscopic remission with a score > 1 
indicating active disease. An UCEIS score of 0-1 was also defined as endoscopic 
remission with a score > 1 indicating active disease.
Corticosteroid and Immunomodulator therapy
Corticosteroid therapy was defined as the use of any oral steroid including 
prednisolone and budesonide. Immunomodulator therapy includes any oral or rectal 
immunomodulator which includes AZA, 6MP, MTX (oral or parenteral), tacrolimus 
(oral or rectal), ciclosporin and mycophenylate. Corticosteroid and immunomodulator 
use was assessed at baseline, 3, 6 and 12 mo.
Safety
The development of infusion reactions, adverse events and serious adverse events 
were all recorded. Infusion reactions were defined as any adverse event that occurred 
on the day, or the day after, the infusion. Adverse events were defined as any 
untoward medical occurrence not resulting in discontinuation of the VDZ or 
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hospitalization. Adverse events were graded as serious if they resulted in 
discontinuation of VDZ, hospitalization of the patient, or patient death.
Statistical analysis
Data for each patient from their first dose of VDZ to either last infusion within the 
study period or cessation of the VDZ were included for analysis. All statistical analysis 
was conducted using SPSS version 24 (IBM Corp, released 2016). Statistical 
significance was set at P < 0.05. Patient demographic and disease profile information 
was described using frequency and percent for categorically classified variables, with 
mean and standard deviation and median and range used to describe scale variables. 
VDZ treatment outcomes are described at baseline, 3, 6 and 12 mo. Sample size varied 
across measures and was reported accordingly.
Two Cox Regression models and Kaplan Meier curves were performed separately 
for each site. The first model examined time (weeks) to remission. Time to censor was 
calculated as the difference between the date of remission (censor event) and the date 
the patient started the study. The second model examined time (weeks) to failure. 
Failure was defined as Partial Mayo clinical score ≥ 2 or MES ≥ 2, or the need for a 
change in the biologic agent, or requiring colectomy. Time to censor was calculated as 
the difference between this date of failure (censor event) and the date the patient 
started the study, truncated to 60 wk. Both models examined the covariates gender, 
disease duration (year), smoking (non–smoker/current smoker or ex smoker), disease 
location, age at which VDZ was given (year), and previous immunomodulator 
exposure. For the failure model, a remission covariate was also included (median split 
≤ 13/> 13 wk of time to remission). For both models where remission or failure 
occurred at the start of the study, a small constant (0.01) was added to the time to 
event variable. Cox model proportional hazard assumption was tested using 
Schoenfeld residuals with no violations. A chi square analysis was used to investigate 
the remission and failure censor variables with anti-TNF, and site differences across 
categorical variables. Disease duration, age vedolizumab started, remission time and 
failure time were examined for normality using Shapiro Wilk and violations were 
noted. Therefore site differences for these continuous variables were examined using 
the non-parametric alternative Mann Whitney U Test. Further Cox Regression models 
and Kaplan Meier curves were performed using the combined data set with site 
included as a variable.
RESULTS
Patient characteristics
Three hundred and thress UC patients (Australia n = 210 and Oxford, United 
Kingdom, n = 93) from 15 centers (Australia n = 14) were included in the study. Of the 
303 patients, patient data was available in 278 at 3 mo, 250 patients at 6 mo and 209 
patients at 12 mo. Of the 303 patients, 15 patients were in remission at the start of VDZ 
and VDZ was commenced due to side effects to the anti-TNF agents, these patients 
were analysed separately at each time point (Figure 1).
Patient demographics and clinical characteristics
Of the total 303 patients, 60% (n = 182) were anti-TNF naïve and VDZ was their first 
biologic agent, while 40% (n = 121) had prior anti-TNF exposure with a secondary 
LOR in 20% (n = 61) and primary LOR in 15% (n = 45). VDZ was commenced in 5% (n 
= 15) of patients due to side-effects from anti-TNF therapy and these patients were in 
clinical remission at VDZ induction, so were analyzed separately. A total of 47% (n = 
143) were female (Table 1).
The median age at which VDZ was started was 35 years (range 16-84 years), while 
the median disease duration was 6 years (range 0.2-48 years) prior to the 
commencement of VDZ. A family history was present in 12% (n = 29) and 81% (n = 
226) were non-smokers at the time of commencing VDZ. All patients were classified by 
the Montreal classification[8] and 56% were diagnosed with UC between the ages of 17-
40 years (n = 170, A2) compared to younger than 17 years in 11% (n = 34, A1) and 33% 
older than 40 years (n = 99, A3). Disease extent was extensive in 56% of patients (n = 
170, E3) with 38% with suffering left-sided colitis (n = 114, E2) and 6% patients with 
proctitis (n = 18, E1). Of all patients, 63% (n = 191) were on steroids at the 
commencement of VDZ, 53% (n = 162) were taking prednisone and 10% (n = 29) 
budesonide. 58% (n = 175) of the patients were on an immunomodulator, with the 
thiopurines (AZA/6MP) being the most commonly used in 45% (n = 136), followed by 
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Table 1 Clinical characteristics of study population
Characteristic Total (n = 303) Australia (n = 210) Oxford (n = 93)
Gender
Female, n (%) 143 (47) 95 (45) 48 (52)
Median age VDZ given (range, yr) 35 (16-84) 36 (19-78) 35 (16-84)
Median disease duration (range, yr) 6 (0.2-48) 7 (1-48) 5.4 (0.2-39.2)
Montreal classification, n (%)
Age
A1 34 (11) 33 (16) 1 (1)
A2 170 (56) 120 (57) 50 (54)
A3 99 (33) 57 (27) 42 (45)
Location
E1 18 (6) 15 (7) 3 (3)
E2 114 (38) 72 (34) 42 (45)
E3 170 (56) 122 (58) 48 (52)
Missing 1 1 0
Family History, n (%) 29 (12) 22 (15) 7 (7)
First degree 19 12 7
Second degree 10 10 0
None 212 126 86
Smoking, n
Never 226 140 86
Current 9 6 3
Ex smoker 45 41 4
Anti-TNF naïve, n (%) 182 (60) 122 (58.1) 60 (65)
Anti-TNF exposed, n (%) 121 (40) 88 (41.9) 33 (35)
Primary LOR 45 (15) 29 (13.8) 16 (17)
Secondary LOR 61 (20) 47 (22.4) 14 (15)
Side-effects 15 (5) 12 (5.7) 3 (3.2)
Steroids at VDZ initiation, n (%) 191 (63) 134 (64) 57 (61.2)
Prednisone 162 (53) 108 (51) 54 (58)
Budesonide 29 (10) 26 (12) 3 (3)
Immunomodulation at VDZ initiation, n (%) 175 (58) 135 (64) 40 (43)
AZA/6MP 136 (45) 108 (51) 28 (30)
Methotrexate 19 (6) 11 (5) 8 (9)
Tacrolimus 17 (6) 16 (8) 1 (1)
Others (Cyclo&Myco) 3 (1) 0 3 (3)
Mean Partial Mayo before VDZ initiation 5 (2-9) 6 (2-9) 5 (2-9)
VDZ: Vedolizumab; min: Minimum; max: Maximum; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss 
of response; AZA: Azathioprine; 6MP: 6-mercaptopurine; Cyclo: Ciclosporine; Myco: Mycophenolate; Init, Initiation.
MTX, tacrolimus, ciclosporine and mycophenolate. The mean partial Mayo score was 5 
(range 2-9) at commencement of VDZ.
No significant differences were observed between the Australian and Oxford 
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Figure 1  Flowchart.
patients for prior anti-TNF exposure (P = 0.36), sex (P = 0.3), family history (P = 0.43), 
and age at which VDZ was started (P = 0.35). Significant differences between the 
Australian and Oxford patients, however, were observed for smoking with more 
Oxford patients having never smoked (P < 0.001) but there was no difference in the 
current smokers at time of VDZ commencement. Immunomodulator usage at the 
commencement of VDZ was greater in Australian than Oxford patients (P < 0.001), 
and the disease duration in Australian patients was longer prior to VDZ 
commencement (P < 0.048).
Assessment at 3 mo, 6 mo and 12 mo
A total of 263 patients were not in remission at commencement of VDZ, and of these 
79% (n = 208) achieved a clinical response and 56% (n = 148) achieved clinical 
remission by 3 mo. Three mo data was missing for 25 patients (9 Australia, 16 Oxford), 
and thus these were not included in the induction analysis but there was data for the 
clinical status of these patients at 6 and 12 mo.
At 3 mo, Australian patients were more likely to achieve response (P = 0.01), but 
were not more likely to achieve remission than Oxford patients (P = 0.58) (Table 2). 
Anti-TNF naïve patients were more likely to achieve both response (P = 0.03) and 
remission (P < 0.001) at 3 mo compared to patients who had prior anti-TNF exposure. 
Within the anti-TNF exposed group, there was no significant difference between the 
patients who had a primary or secondary LOR to an anti-TNF agent in achieving 
clinical response (P = 0.9) or remission (P = 0.8) to VDZ at 3 mo.
Of the total 238 patients assessed at 6 mo, 62% (n = 147) were in remission and of the 
201 patients assessed at 12 mo, 60% (n = 120) were in remission (Table 3). No 
significant difference was found between Australia and Oxford in the number of 
patients in remission at 6 mo (P = 0.3) or at 12 mo (P = 0.09). Anti-TNF naïve patients 
were more likely to achieve remission both at 6 mo (P < 0.001) and 12 mo (P = 0.03) 
than those previously exposed. Within the anti-TNF exposed group, there was no 
significant difference between the patients who had primary or secondary LOR to anti-
TNF agents in clinical remission at 6 mo (P = 0.2) or 12 mo (P = 0.3).
Of the 15 patients who were in remission at the start of VDZ, where the indication 
was side effects to anti-TNF agents, 66% (n = 10/15) at 3 mo, 58% (n = 7/12) at 6 mo, 
50% (n = 4/8) at 1 year were still in clinical remission.
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Table 2 Response and remission at 3 mo of vedolizumab therapy
Total Australia Oxford P value
Response, n (%) 208 (79) 157 (83) 51 (70) 0.01
Remission, n (%) 148 (56) 104 (55) 44 (59) 0.58
Total Anti-TNF naive Anti-TNF exposed P value
Response, n (%) 208 (79) 138 (83) 70 (72) 0.03
Remission, n (%) 148 (56) 109 (66) 39 (40) < 0.001
Anti-TNF exposed Primary LOR Secondary LOR P value
Response, n (%) 70 (72) 30 (73) 40 (71) 0.85
Remission, n (%) 39 (40) 16 (39) 23 (41) 0.83
VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response to anti-TNF agent; Secondary LOR: Secondary loss of response to 
anti-TNF agent.
Table 3 Remission at 6 mo and 12 mo of vedolizumab therapy
Total Australia Oxford P value
Remission at 6 mo, n (%) 147 (62) 110/173(64) 37/65 (57) 0.34
Remission at 12 mo, n (%) 120/201 (60) 87/138 (63) 33/65 (52) 0.09
Total Anti-TNF naive Anti-TNF exposed
Remission at 6 mo, n (%) 147/238 (62) 103/142 (73) 44/96 (46) < 0.001
Remission at 12 mo, n (%) 120/201 (60) 76/115 (66) 44/86 (51) 0.03
Anti-TNF exposed Primary LOR Secondary LOR
Remission at 6 mo, n (%) 44/96 (46) 16/42 (38) 28/54 (52) 0.18
Remission at 12 mo, n (%) 44/86 (51) 17/38 (44) 27/48 (56) 0.28
VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response to anti-TNF agent; Secondary LOR: Secondary loss of response to 
anti-TNF agent.
Endoscopy
A total of 108 patients had endoscopy at 6 mo, 78 in Australia and 30 in Oxford. Of the 
Oxford patients, 43% (13/30) had an UCEIS of ≤ 1 indicating endoscopic remission. Of 
the Australian patients, 69% (54/78) had an MES of 0-1 indicating endoscopic 
remission. A significantly greater percentage of patients achieved endoscopic 
remission in Australia compared to Oxford (P = 0.01). A MES score of 0 was achieved 
in 31% (24/78) of the Australian cohort. A MES ≥ 2 was reported in 31% (n = 24) of 
Australian patients and a UCEIS ≥ 2 was reported in 57% (n = 17) of Oxford patients.
Time to remission
A total of 224 (73.9%) patients were censored as being in “remission”. While 
controlling for the site, univariate cox regression models for time to remission found 
no significant associations for gender (P = 0.3), disease duration (P = 0.6), smoking 
status (P = 0.9), age at which VDZ was given (P = 0.7), immunomodulator exposure (P 
= 0.8) and these were also not significant when considered with anti-TNF exposure. 
The final model included anti-TNF exposure and the site with the Log Rank (Mantel-
Cox) reporting a significant difference (P < 0.001) between time-to-remission for anti-
TNF exposure, with anti-TNF naïve patients 1.8 times more likely to achieve clinical 
remission (95%CI: 1.3-2.3) (Figure 2).
Time to failure
A total of 84 (27.7%) patients were censored as ‘failure’. Controlling for site, univariate 
cox regression models for time-to-failure found no significant associations for gender (
P = 0.4), smoking status (P = 0.3), age at which VDZ was given (P = 0.9), 
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Figure 2  Cumulative remission rate of anti-tumor necrosis factor naïve patients to vedolizumab therapy (vs anti-tumor necrosis factor 
exposed patients, P < 0.001).
immunomodulator exposure (P = 0.2). These factors remained not significant when 
considered with anti-TNF exposure. Disease duration was significant (OR = 0.95, 
95%CI: 0.93-1.00 P = 0.048), however, was no longer significant when considered with 
anti-TNF exposure. The final model included anti-TNF exposure and site with the Log 
Rank (Mantel-Cox) reporting significant difference (P = 0.011) between time-to-failure 
for anti-TNF groups with anti-TNF exposure patients 1.8 times more likely to lose 
response (95%CI: 1.16-2.75) (Figure 3).
Safety
The tolerability of VDZ was high with only 8% (n = 25) of all patients reporting an 
adverse event. Infections (7%, n = 21) were by far the most common adverse event. 
Two patients reported a serious infection, one was Haemophagocytic syndrome due to 
Cytomegalovirus and another was from Klebsiella sepsis, both from Australia and 
both patients were on dual immunosuppression thorough out the study period. A 
total of 9 patients who received VDZ reported respiratory complications of whom 4 
patients reported sinusitis, 2 patients an upper respiratory tract infection, one patient 
each of nasopharyngitis, pharyngitis and pneumonia. Gastrointestinal infections were 
reported in 8 patients. Clostridium difficile was the most common gastrointestinal 
infection (4 patients) followed by Strongyloides (one patient), Campylobacter (one 
patient), and Salmonella (one patient). A buttock abscess was reported in one patient. 
Oral thrush was reported in an Oxford patient was attributed to VDZ use. The other 
complications due to VDZ use reported in our cohort during the study period include 
rash in one patient, delayed hypersensitivity in one patient and arthralgia and 
headaches in another patient (Table 4). No deaths were attributed to VDZ use.
A colectomy was undertaken in 11% (n = 32) patients by 12 mo. No significant 
difference (P = 0.25) in the number of patients requiring colectomy in Australia (n = 
19/210) and Oxford (n = 13/93) was observed. Anti-TNF exposed patients (23/121) 
were more likely to require colectomy compared to anti-TNF naïve (9/182) by 12 mo (
P = 0.0005) but when patients with primary and secondary LOR to anti-TNF agents 
were compared, no significant difference was noted (Table 5).
DISCUSSION
In this study of 303 UC patients treated with VDZ from 15 specialist IBD centers in two 
countries, VDZ was noted to be both safe and effective. This study, and the GETAID 
studies[9], are the only studies where VDZ data is collected from multiple centers 
encompassing two countries, thus effectively reducing physician, site and country 
biases.
The key findings in this cohort were that the week 12 response in UC was 79% while 
remission rates were 56%, 62% and 60% at 3, 6 and 12 mo respectively. No differences 
were observed between the two countries in achieving remission at all time points. 
Anti-TNF-exposed patients, however, were almost twice as likely to lose response to 
VDZ compared to anti-TNF naïve patients but no difference in VDZ outcomes were 
observed between patients who had a primary and secondary LOR to anti-TNF agents. 
Pulusu SSR et al. Vedolizumab for ulcerative colitis
WJG https://www.wjgnet.com 4437 August 14, 2020 Volume 26 Issue 30
Table 4 Complications of vedolizumab therapy
Complication Australia (n = 20) Oxford (n = 5)
URTI (2) Pneumonia (1)
Sinusitis (4) Pharyngitis (1)
Respiratory infections
Nasopharyngitis (1)
Strongyloidis (1) Gastroenteritis (1)
Clostridium difficile (4) Buttock abscess (1)
Campylobacter (1) Oral Thrush (1)
Gastrointestinal Infections
Salmonella (1)
Haemophagocytic syndrome due to CMV (1)Serious infections
Klebsiella (1)
NA
Rash (1)
Delayed hypersensitivity reaction (1)
Others
Arthralgia and Headaches (1)
NA
VDZ: Vedolizumab; URTI: Upper respiratory tract infection; NA: Not applicable.
Table 5 Colectomy at 12 mo of vedolizumab therapy
Colectomy, n Australia Oxford P value
19/210 13/93 0.25
Colectomy, n Anti-TNF naive Anti-TNF exposed P value
9/182 23/121 0.0005
Colectomy, n Primary LOS Secondary LOS P value
10/45 23/61 0.795
VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss of response.
Figure 3  Cumulative loss of response of anti-tumor necrosis factor exposed patients to Vedolizumab therapy (vs anti-tumor necrosis 
factor naïve patients, P = 0.011).
Adverse events were observed in 8% of patients and 11% patients required colectomy 
by 12 mo.
Our results were comparable to prior work from other real world studies. A 
Swedish real world study observed that 64% of UC patients achieved clinical 
remission at the end of the follow-up period[10], while a French study demonstrated 
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that 40.5% were in steroid-free clinic remission at week 54[11]. The discrepancy in the 
clinical response rates could be explained by the difference in clinical characteristics of 
the patients entering the study and also different clinical criteria (steroid-free 
remission in French study) used to assess the patients. Similarly, other real world data 
have shown that prior exposure to anti-TNF agents reduces VDZ effectiveness, but no 
difference in VDZ outcomes when the patients had either primary or secondary LOR 
to anti-TNF agents is in line with our findings[12]. The adverse event profile with VDZ 
treatment was also similar to what has been previously reported[13].
Mucosal healing in UC is associated with improved long-term clinical outcomes and 
STRIDE guidelines identified it as a therapeutic goal[1]. With MES as an endpoint, we 
report mucosal healing rates of 69% in Australian Cohort at 6 mo compared to 50% in 
ACT1, 46% in ACT2 at week 30 with Infliximab[14], 59% in PURSUIT at week 30 with 
Golimumab[15] , 25% in ULTRA2 at week 52 with adalimumab[16], 51% in GEMINI1 with 
VDZ at week 52[5].The high mucosal healing rates observed in our study could be due 
to high concomitant immunomodulator use in Australia(64%), however further 
prospective studies are needed to prove the role of immunomodulator use with VDZ.
We chose week 12 to assess the response and remission, in contrast to GEMINI 1 
time of assessment for response at week 6[5]. This was done in accordance with 
Australian PBS criteria, which stipulates that patients must be in remission after 
induction at clinic review before applying for maintenance VDZ. It appears, however, 
that the full effect of VDZ may take longer than 12 wk as a longer duration of 
treatment is associated with a higher rate remission at 6 (62%) than at 3 mo (56%). This 
study thus suggests that the PBS funding criteria may need to be re-attended to benefit 
the patients. Compared to its predecessor Natalizumab, an alpha4 antagonist, VDZ is a 
more selective integrin antagonist blocking only alpha4beta7 and thus does not effect 
lymphocyte trafficking to central nervous system, thereby theoretically eliminating the 
risk of progressive multifocal leukoencephalopathy (PML), a catastrophic side effect of 
Natalizumab[17]. No case of PML occurred in our study or any other previous studies 
with VDZ[18,19].
More Australian patients compared to Oxford patients achieved clinical response at 
3 mo (83% vs 70% P = 0.01) and endoscopic remission at 6 mo (69% vs 43% P = 0.01). 
This may be due to more patients on concomitant immunomodulation in Australia 
compared to Oxford (64% vs 43% at VDZ initiation). Further analysis of our data and 
more prospective studies need to be done to define the role of concomitant 
immunomodulation with VDZ.
Our observed rate of VDZ efficacy at 12 mo in UC (60%) was comparable to the 
rates reported with anti-TNF agents[20,21]. While there are no head to head randomized 
control trials comparing VDZ and infliximab in UC, VDZ showed a significantly better 
durable clinical response (OR = 3.18, 95%CI: 1.14-9.20) and clinical remission (OR = 
2.93, 95%CI: 1.03-8.28) when compared to infliximab in a network meta-analysis[22]. 
With no major safety concerns[23], in the treatment algorithm ladder of UC, we argue 
that VDZ should be considered as the first biologic when conventional treatments fail 
due to its gut selectivity. This is most relevant in patients at high risk of serious 
infections such as the elderly, those with chronic obstructive airway disease or cardiac 
disease. If cost allows, it should even be considered before conventional treatment 
such as AZA due to the same feature and with more and more biosimilars reducing 
the cost of biologics we may see this in future.
VDZ is also an attractive option in patients who have failed prior anti-TNF agent. 
Anti-TNF therapy is effective for the treatment of moderate to severe UC, however a 
significant proportion of patients either fail to respond to anti-TNF therapy termed or 
lose response with time[24]. Second and third anti-TNF agents can be used in such 
patients, however, it is a game of diminishing returns, as Golimumab efficacy data has 
shown that clinical response diminishes with each subsequent anti-TNF agent[25]. 
Rather than giving another anti-TNF agent, VDZ provides a unique mechanism of 
action with gut selectivity and less side effects. VDZ does work in anti-TNF refractory 
IBD patients[26] and our study supports this with 51% of TNF exposed patients 
achieving remission at 12 mo with VDZ therapy.
There are several limitations to our study, the most significant of which is 
retrospective review of the data (although the data in Australia pertaining to each 
VDZ application to PBS was collected prospectively). Different endoscopic assessment 
scores were used in Australia and United Kingdom, although a significant correlation 
was found between the two scores in a recent study[27]. There was consistency, 
however, in the clinical and endoscopic outcomes across the institutions. One another 
limitation is we did not report the number of patients who were steroid free and on 
immunomodulators at different time points in our study although our aim is to look at 
that in future by obtaining further information from the centers.
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As more and more biologic agents become available for the treatment of IBD, the 
role of VDZ needs to be defined. Real-world data is important in developing treatment 
algorithms, which will ultimately help physicians make important treatment decisions 
in complex IBD patients. This study has shown that VDZ is safe and effective in 
achieving clinical and endoscopic remission in UC patients.
ARTICLE HIGHLIGHTS
Research background
Vedolizumab (VDZ) is a gut selective anti-integrin used for treatment of ulcerative 
colitis (UC). Evidence needed to assess it efficacy and safety in a real world setting.
Research motivation
Efficacy and safety of VDZ needs to be assessed, involving multiple inflammatory 
bowel disease (IBD) centers from two countries to reduce physician, site and country 
biases.
Research objectives
In this real world study, we aim to assess the clinical response, clinical, endoscopic 
remission and the factors influencing them in UC patients from Australia and Oxford 
in United Kingdom treated with VDZ.
Research methods
Retrospective review of prospectively entered patient database, treated with VDZ. 
Three hundred and three UC patients from 14 Australian centers and Oxford (United 
Kingdom) were included. Clinical response and remission was assessed at 3, 6 and 12 
mo using Mayo score across all centers. Endoscopic remission was assessed at 6 mo 
using mayo endoscopic score in Australia and ulcerative colitis endoscopic score of 
severity score in Oxford. Cox regression models and Kaplan Meier curves were 
performed to assess the time to remission, time to failure and the covariates 
influencing them. Safety was assessed through adverse event reporting.
Research results
Clinical response for all patients was 79% at 3 mo and number of patients achieving 
clinical remission increased from 3 mo (56%) to 6 mo (62%) and remained almost 
stable at 12 mo (60%). No significant difference was observed between the two 
countries in achieving clinical remission at all points and a significantly greater 
proportion of Australian patients achieved mucosal healing compared to Oxford, 
which could be due to more patients using concomitant immunomodulation in 
Australia. Anti-tumor necrosis factor (anti-TNF) exposed patients were almost twice 
more likely to lose response to VDZ compared to anti-TNF naïve patients but no 
difference in outcomes were observed between patients who had a primary and 
secondary loss of response to anti-TNF agents. The role of concomitant 
immunomodulation in achieving above outcomes need to be elucidated in future 
prospective studies.
Research conclusions
VDZ can be safely and effectively used to treat UC patients in a real world setting. 
However patients who had prior anti-TNF therapy were more likely to fail compared 
to anti-TNF naïve patients.
Research perspective
VDZ use was reviewed in real world setting involving multiple IBD centers from two 
countries. This study helps physicians find VDZ its place in the treatment algorithm of 
complex IBD patient management. Future prospective studies are needed to evaluate 
the benefit of using concomitant immunomodulation with VDZ.
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